Partner Headlines - AMGN

  1. Biotech ETFs Lead Q3 Rally: XBI Breaks Out

    TalkMarkets
  2. 2 Biotech Funds Leading Nascent Bull Market: Which Is Right For ...

    Investors Business Daily
  3. QQQ ETF Posts 52-Week High; Energy Stocks Sag As Oil Drops To ...

    Investors Business Daily
  4. What's Driving The Biotech Stock Rally? And Will It Last?

    Investors Business Daily
  5. Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch ...

    Investors Business Daily
  6. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline ...

    Investors Business Daily
  7. Amgen Beats Q2 Earnings Estimates, Raises Guidance

    Investors Business Daily
  8. Facebook, GoPro, Amgen Beat; Whole Foods Disappoints

    Investors Business Daily
  9. Nasdaq Up As Fed Stands Pat On Rates; Will Apple Break Its Downtrend?

    Investors Business Daily
  10. Alder Biopharma Migraine Drug Holds Up After 6 Months

    Investors Business Daily
  11. This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or ...

    Investors Business Daily
  12. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, ...

    Investors Business Daily
  13. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  14. Chardan Upgrades Regeneron Amid Relative Underperformance To ...

    Benzinga
  15. Gilead, Johnson & Johnson or Roche?

    GuruFocus
  16. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga
  17. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement ...

    Benzinga
  18. The Generic Drug Battle

    Benzinga
  19. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD
  20. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, ...

    Benzinga
  21. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga
  22. Leerink Is Back On Board The Biotech Train

    Benzinga
  23. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  24. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  25. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  26. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  27. Earnings Recap For January 28

    Benzinga
  28. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  29. Regeneron Is Now A Sell For Chardan

    Benzinga
  30. Big Earnings Expectations For Big Biotech

    Benzinga
  31. Amgen's Vectibix, Best Supportive Care Improves Overall Survival ...

    Benzinga
  32. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for ...

    Benzinga
  33. Medicines Company Spikes On Report Of Possible Sale

    IBD
  34. Jim Cramer Likes Amgen

    Benzinga
  35. Write A Prescription For This Healthcare ETF

    Benzinga
  36. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD
  37. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD
  38. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga
  39. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  40. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; ...

    Benzinga
  41. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire ...

    Benzinga
  42. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers ...

    Benzinga
  43. Benzinga's Top #PreMarket Gainers

    Benzinga
  44. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus
  45. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  46. Dividend Growth Skids To Halt For S&P 500

    IBD
  47. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  48. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga
  49. Big Cap 20 Stocks Setting Up In Bases

    IBD
  50. Analyzing Amgen's Dividend Hike

    GuruFocus
  51. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga
  52. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma ...

    Benzinga
  53. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy ...

    Benzinga
  54. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD
  55. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD
  56. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus
  57. Benzinga's Top Upgrades

    Benzinga
  58. Benzinga's Top #PreMarket Gainers

    Benzinga
  59. Amgen Shares Move Higher Following Morgan Stanley Upgrade To ...

    Benzinga
  60. Amgen Submits Application to EMA To Expand Indication Of Kyprolis ...

    Benzinga
  61. Amgen Announces New Analyses Presented At #ASH2015 Demonstrate ...

    Benzinga
  62. Amgen Announces Pivotal Head-To-Head ENDEAVOR Study Results Published ...

    Benzinga
  63. Amgen, Merck target cancer

    IBD
  64. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  65. LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

    IBD
  66. Application for Amgen's Biosimilar Candidate to Humira, Submitted ...

    Benzinga
  67. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga
  68. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  69. EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia ...

    Benzinga
  70. CVS Makes Amgen New BFF

    IBD
  71. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD
  72. European Commission Approves Kyprolis® (carfilzomib) For Combination ...

    Benzinga
  73. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  74. Regeneron Tests Buy Point As New Drug Shows Promise

    IBD
  75. Regeneron Recovers From Clinton Biotech Beat Down

    IBD
  76. Benzinga's M&A Chatter for Tuesday November 10, 2015

    Benzinga
  77. Amgen Issues Presentation of Results from Phase 3 Study Showing ...

    Benzinga
  78. Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority ...

    Benzinga
  79. ICYMI: Berkshire Hathaway Just Reported Earnings Of $2,769 Per ...

    Benzinga
  80. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga
  81. Regeneron Q3 Beats Views, But Praluent Launch Slow

    IBD
  82. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD
  83. 10 Stocks To Watch For October 29, 2015

    Benzinga
  84. Buffalo Wild, GoPro Among Flurry Of Late Wed. Earnings

    IBD
  85. Amgen Crushes EPS Views

    IBD
  86. Amgen Q3 Earnings Beat; Sales Growth Best In Years

    IBD
  87. Amgen Posts Upbeat Q3 Results, Lifts Forecast

    Benzinga
  88. Lifelock, Yelp Surge Following Earnings Report; B-Dubs, GoPro ...

    Benzinga
  89. Wild Short Interest Swings For Three Top Biotech Stocks

    Benzinga
  90. Keep an Eye on These 10 Stocks for October 28, 2015

    Benzinga
  91. Stocks End Lower; Apple Up, Twitter Down After Hours

    IBD
  92. Amgen and Cytokinetics Announce Positive Top-Line Results From ...

    Benzinga
  93. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  94. 10 S&P 100 Companies Paying The Highest And Lowest Taxes

    Benzinga
  95. Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene ...

    Benzinga
  96. Cowen: In Biotech Earnings We Trust

    Benzinga
  97. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  98. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  99. Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy ...

    Benzinga
  100. Eli Lilly Pulls Cholesterol Drug

    IBD
Trading Center